Payment overview · 2025
General Payments
$714.26
27 reported records · 15 companies
Healthcare provider profile · identity verified
Santanu Som, MD, DO
Allopathic & Osteopathic Physicians|Family Medicine · NIAGARA FALLS, NY · NPI 1568678316
Verified facts
What the public records show
CMS Open Payments records show Santanu Som, MD, DO received $714.26 in general payments during 2025 across 27 reported records.
Axsome Therapeutics, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $154.49 | 21.6% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $147.46 | 20.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.81 | 10.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.40 | 8.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.63 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.09 | 4.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.90 | 4.9% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $30.95 | 4.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.16 | 4.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $27.11 | 3.8% | 1 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $19.96 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.49 | 2.6% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $17.68 | 2.5% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $17.57 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.56 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.26 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $147.46 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $119.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $30.95 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $27.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 141 | 17 |
| Atorvastatin Calcium | Atorvastatin Calcium | 135 | 39 |
| Gabapentin | Gabapentin | 133 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 125 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 24 |
| Metformin Hcl | Metformin Hcl | 103 | 17 |
| Lisinopril | Lisinopril | 97 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 95 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 80 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 17 |
| Olanzapine | Olanzapine | 66 | suppressed |
| Furosemide | Furosemide | 64 | 18 |
| Sertraline Hcl | Sertraline Hcl | 64 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 13 |
| Levetiracetam | Levetiracetam | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | 12 |
| Bumetanide | Bumetanide | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 39 | 13 |
| Carvedilol | Carvedilol | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 35 | 13 |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 25 |
| Risperidone | Risperidone | 31 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Baclofen | Baclofen | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Losartan Potassium | Losartan Potassium | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 18 |
| Clozapine | Clozapine | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Finasteride | Finasteride | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Trexall | Methotrexate Sodium | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.26 · 27 records | Axsome Therapeutics, Inc. | ABILIFY MAINTENA, AIRSUPRA, Auvelity, Azstarys, CAPLYTA, Evoke, FASENRA, Grastek, JOURNAVX, Korlym, OTEZLA, Odactra, Ozempic, REPATHA, Ragwitek, Rybelsus, SPRAVATO, SPRINT PNS System, Symbravo, UBRELVY, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error